NASDAQ: QUITAchieve Life Sciences Inc Stock
$6.45+0.05 (+0.78%)
Updated Nov 11, 2026
QUIT Price
$6.45
Fair Value Price
$0.14
Market Cap
$709.72M
52 Week Low
$2.62
52 Week High
$8.64
P/E
-4.74x
P/B
3.93x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$111.71M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
-$44M
Beta
1.05
Next Earnings
Nov 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
QUIT Overview
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Bothell, WA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine QUIT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
QUIT
Ranked#265 of 452
Ranked#265 of 452
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.52 | A | |
| $959.41 | A | |
| $419.98 | A |
Be the first to know about important QUIT news, forecast changes, insider trades & much more!
QUIT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how QUIT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QUIT ($6.45) is overvalued by 4,606.82% relative to our estimate of its Fair Value price of $0.14 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
QUIT ($6.45) is not significantly undervalued (4,606.82%) relative to our estimate of its Fair Value price of $0.14 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
QUIT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more QUIT due diligence checks available for Premium users.
Valuation
QUIT fair value
Fair Value of QUIT stock based on Discounted Cash Flow (DCF)
Price
$6.45
Fair Value
$0.14
Overvalued by
4,606.82%
QUIT ($6.45) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
QUIT ($6.45) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
QUIT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
QUIT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.74x
Industry
17.04x
Market
42.33x
QUIT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.93x
Industry
5.31x
QUIT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QUIT's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.1M
Profit Margin
0%
QUIT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$206.4M
Liabilities
$25.7M
Debt to equity
0.14
QUIT's short-term assets ($203.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QUIT's short-term assets ($203.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QUIT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
QUIT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.4M
Investing
-$1.7M
Financing
$21.6M
QUIT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QUIT vs Biotech Stocks
Achieve Life Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.